17,261 trials
Metastatic Non-squamous Non Small Cell Lung Cancer
Primary: The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per…
Hormone-Resistant Prostate Cancer · Recurrent Prostate Carcinoma
Primary: PSA Response Rate — 1; 2 Participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Progeria · Hutchinson-Gilford Syndrome
Primary: Proportion of Participants With Successful Rate of Weight Gain — 0.36 proportion of participants
Non-Small Cell Lung Cancer
Primary: To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only — 6.3; 11.9 months
Depressive Disorder, Major
Primary: ACC Glx/Water — 19.21; 18.99; 19.28; 20.61 ratio * 10^-4
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Overall Survival — 25 Participants
Acute Myeloid Leukemia in Remission · de Novo Myelodysplastic Syndrome · Fanconi Anemia
Primary: Number of Patients Who Engraft at Each Dose of TBI Used — 5; 1 Participants
B-cell Chronic Lymphocytic Leukemia · Nodal Marginal Zone B-cell Lymphoma · Recurrent Adult Burkitt Lymphoma
Primary: Treatment Related Mortality (TRM) — 16 percent
Alzheimer's Disease
Primary: Number of Participants With Adverse Events (AE's) — 25; 2; 8; 3 participants
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069
Borderline Hypokalemia
Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates) — 23; 9; 12; 9 Participants — p=0.03
Myeloma
Primary: Phase I - Maximum Tolerated Dose (MTD) — 400 mg
Gonorrhea
Primary: Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit — 29; 37 Participants